drugset / Trial / NCT00770965
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either AIN457 at one of the three doses studied or placebo.
Timeline
- Start
- 2008-09-10
- Primary completion
- 2009-09-17
- Completion
- 2009-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 3 mg/kg | Intravenous |